CoMentis
South San Francisco
About CoMentis
CoMentis is a biotech company focused on the research and development of small molecule drugs to treat neurovascular diseases such as Alzheimer's disease (AD), age-related macular degeneration (AMD) and other cognitive disorders. Originally founded in 2004 as Athenagen, Inc., the company was re-named CoMentis following its August 2006 merger with Zapaq, Inc., which created a leading neurovascular disease franchise.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $107.5M
- Funding stage: Late Stage Venture
- Last round: Series E (Mar 2016)
- Website: comentis.com
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/comentis-225743 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.